Login to Your Account



Bioven Emerges from Stealth with Phase III Cancer Vaccine


Wednesday, September 5, 2012

LONDON – A company based in Aberdeen, Scotland, that was founded and funded in Malaysia, with the aim of commercializing cancer vaccines discovered in Cuba, has announced the start of a pivotal Phase III trial of its lead product, BV-NSCLC-001.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription